- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02329132
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Study Overview
Detailed Description
Diabetic retinopathy is characterized by the retinal non-perfusion areas (the retinal hypoxia), leading to the upregulation of vascular endothelial growth factors (VEGF). Subsequently, VEGF causes increased vascular leakage, retinal vasodilation, and the development of macular edema. Based on these mechanisms, the oxygen saturation in the retinal vessels or retinal oxygen consumption would reflect the degree of underlying retinal hypoxia. Injections of anti-VEGF agents (ranibizumab) reduce the macular edema and may suppress the progression of retinal nonperfusion area. However, so far, limited information is available on the effects of anti-VEGF agents (ranibizumab) to the retinal hypoxic conditions. In addition, baseline conditions of the oxygen saturation in the retinal vessels may provide us the predictive information on the treatment efficacy of anti-VEGF agents (ranibizumab) to the diabetic macular edema.
Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of retinal nonperfusion area. This protective effect would cause the increase of the oxygen consumption in the diabetic retina. We expect that the current study using the retinal oximetry would show the protective effects of ranibizumab on the hypoxia in the diabetic retina.
In addition, previous studies showed an increased VEGF level in the aqueous humor or the vitreous, depending on the progression of the diabetic retinopathy. The level of VEGF in the aqueous humor would reflect the retinal hypoxia and may be of use for the prediction of the visual prognosis. This study is designed to analyze the effects of ranibizumab (Lucentis) to the retinal oxygen saturation or consumption in eyes with diabetic macular edema.
Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination. The principal criteria for retreatment are the reduction of VA, foveal and extrafoveal macular edema or serous retinal detachment on OCT.
At each visit, both eyes are scheduled to be examined with VA measurement, OCT examination, oxygen saturation measurement. Just before the first injection of ranibizumab, aqueous humor will be extracted with a pipet.
Retinal oximetry will be performed with Oxymap (Oxymap ehf, Reykjavik, Iceland). Briefly, the device simultaneously acquires digital images at two wavelengths and automatically tracks retinal vessels on both images. Retinal vessel oxygen saturation is estimated by spectrophotometric analysis of light reflected from retinal vessels and from the immediately surrounding retina. Oxygen saturation measurements are made on major temporal arteries and veins. Briefly, the first and second degree vessels are used, with the addition of third degree vessels in images where peripapillary haemorrhage prevented analysis close to the optic disc. Vessel segments chosen for analysis are used consistently for consecutive measurements in the same retina.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Kagawa
-
Miki, Kagawa, Japan, 761-0793
- Kagawa University Faculty of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diabetic macular edema involving the foveal center
- Male or female of aged 18 years or older
- Decrease of visual acuity (VA) due to macular edema
- Signed informed consent form
Exclusion Criteria:
- Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation
- Ocular disorders in the study eye that may confound interpretation of study results
- History of vitrectomy surgery, or other surgical intervention other than the cataract surgery
- The pregnant or lactating woman
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of retinal oxygen saturation and consumption from baseline at 6 months
Time Frame: At 6 months after ranibizumab (Lucentis) treatment.
|
Retinal oximetry will be performed with Oxymap (Oxymap ehf, Reykjavik, Iceland).
Briefly, the device simultaneously acquires digital images at two wavelengths and automatically tracks retinal vessels on both images.
Retinal vessel oxygen saturation is estimated by spectrophotometric analysis of light reflected from retinal vessels and from the immediately surrounding retina.
Oxygen saturation measurements are made on major temporal arteries and veins.
Briefly, the first and second degree vessels are used, with the addition of third degree vessels in images where peripapillary haemorrhage prevented analysis close to the optic disc.
Vessel segments chosen for analysis are used consistently for consecutive measurements in the same retina.
Oxygen saturation measurements will be measured at each visit for 6 months.
|
At 6 months after ranibizumab (Lucentis) treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: AKITAKA TSUJIKAWA, MD, Kagawa Univerisity Faculty of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H26-000
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted